54998-00-4

Basic information

• Product Name: 4-(3-Amino-4-nitrophenyl)morpholine
• Synonyms: 5-MORPHOLIN-4-YL-2-NITRO-ANILINE;5-MORPHOLIN-4-YL-2-NITRO-PHENYLAMINE;5-MORPHOLINO-2-NITROANILINE;BUTTPARK 17\04-70;4-(3-Amino-4-nitrophenyl)morpholine;5-morpholino-2-nitrobenzenamine
• CAS NO: 54998-00-4
• Molecular Formula: C₁₀H₁₃N₃O₃
• Molecular Weight: 223.23
• Mol File: 54998-00-4.mol
• Article Data: 25

Chemical Properties

• Melting Point: 182-185°C
• Boiling Point: 469.7°C at 760 mmHg
• Flash Point: 237.9°C
• Appearance: /
• Density: 1.337g/cm³
• Vapor Pressure: 5.38E-09mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: 2-8°C
• PKA: 0.86±0.40(Predicted)
• CAS DataBase Reference: 4-(3-Amino-4-nitrophenyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Amino-4-nitrophenyl)morpholine(54998-00-4)
• EPA Substance Registry System: 4-(3-Amino-4-nitrophenyl)morpholine(54998-00-4)

Safety Data

• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 54998-00-4(Hazardous Substances Data)

Usage

General Description

4-(3-Amino-4-nitrophenyl)morpholine is a chemical compound with the molecular formula C10H13N3O3. It is an aromatic amine derivative containing a morpholine ring, and it has both amino and nitro substituents attached to the phenyl ring. 4-(3-Amino-4-nitrophenyl)morpholine is used in the synthesis of pharmaceuticals, specifically in the development of anti-inflammatory and anti-cancer drugs. It has also been studied for its potential antiparasitic and antimicrobial properties. Additionally, 4-(3-Amino-4-nitrophenyl)morpholine has been investigated for its role in antioxidant and neuroprotective applications. Overall, this chemical has potential uses in the pharmaceutical and medical industries due to its diverse range of properties and potential therapeutic effects.

InChI:InChI=1/C10H13N3O3/c11-9-7-8(1-2-10(9)13(14)15)12-3-5-16-6-4-12/h1-2,7H,3-6,11H2

Upstream product

• 110-91-8 morpholine 
• 1635-61-6 5-chloro-2-nitroaniline 
• 68-12-2 N,N-dimethyl-formamide 
• 5228-61-5 5-bromo-2-nitroaniline 
• 64-17-5 ethanol 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 119421-28-2 4-morpholinobenzene-1,2-diamine 
• 897446-65-0 2-cyclohexyl-N-(5-morpholin-4-yl-2-nitrophenyl)-2-phenylacetamide 
• 402948-33-8 ethyl 2-(5-morpholin-4-ylbenzimidazol-2-yl)acetate 
• 949570-75-6 methyl 4-chloro-2-(5-morpholino-2-nitrophenylamino)benzoate 
• 111861-06-4 5⁽⁶⁾-Morpholino-2-(4-nitrophenyl)benzimidazole 
• 1227867-14-2 6-[(2-amino-5-morpholinophenyl)amino]-4-[(3,5-difluorobenzyl)amino]pyridine-3-carboxyamide 
• 1187383-65-8 (2S)-N-{4-(5-[2-[(4-(benzyloxy)phenyl)-6-morpholino]benzimidazol-1-yl]pentyl)oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 1187383-66-9 (2S)-N-{4-(5-[2-[(4-(benzyloxy)phenyl)-6-morpholino]benzimidazol-1-yl]pentyl)oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 1187383-55-6 7-methoxy-8-{5-[2-[(4-(benzyloxy)phenyl)-6-morpholino]benzimidazol-1-yl]pentyl}oxy-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one 
• 1187383-72-7 4-{2-[4-(benzyloxy)phenyl]benzimidazol-6-yl}morpholine 

Relevant articles and documents

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

Selective hydrogenation of nitroarenes under mild conditions by the optimization of active sites in a well defined Co?NC catalyst

The catalytic hydrogenation of aromatic nitro compounds containing multiple functional groups into amino compounds with high conversion rates, selectivity, and stability under mild conditions is a great challenge. Herein, a well defined catalyst (Co?NC) is prepared through the pyrolysis of the Co-centered metal-organic framework (MOF) at the optimized temperature. The as-synthesized catalyst exhibits a high conversion rate and selectivity for the hydrogenation of 12 aromatic nitro compounds with different competing groups into desired amino compounds with hydrazine hydrate under mild conditions (80 °C, 30 min, and 1 atm). The catalyst also shows excellent stability and can be reused over 20 times without considerably losing its activity. It is found that the Co-Nx site is the main active site for catalytic hydrogenation, and the Mott-Schottky effect between the surface Co NPs and N-doped carbon can further promote the hydrogenation reaction. EXAFS, TEM, XPS, and Raman analyses confirm that cobalt nanoparticles (NPs) are properly encapsulated by the N-doped carbon matrix at the optimized temperature, and the Co species maintain a high spin state after the catalysis, which may be responsible for the high performance of Co?NC. This work demonstrates not only a highly efficient catalyst for hydrogenation under mild conditions, but also provides insight into the active sites in Co-based catalysts for hydrogenation.

Heterocycle type derivative and preparing method and pharmaceutical application thereof

The invention relates to a novel heterocycle type derivative, a preparing method thereof, a medicine composition containing the derivative and application of the heterocycle type derivative as therapeutic agent, particularly an FGFR4 inhibitor. The preferable compound has a good inhibiting effect on FGFR4.